Results 21 to 30 of about 54,594 (319)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

Biomolecules, 2020
Ligand-targeted toxins (LTTs) are bioengineered molecules which are composed of a targeting component linked to a toxin that induces cell death once the LTT binds its target. Bispecific targeting allows for the simultaneous targeting of two receptors. In
Felix Oh, Jaime F. Modiano, Veronika Bachanova, Daniel A. Vallera   +3 more
doaj   +1 more source

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting

Molecules, 2019
A promising strategy in cancer immunotherapy is the employment of a bispecific agent that can bind with both tumor markers and immunocytes for recruitment of lymphocytes to tumor sites and enhancement of anticancer immune reactions.
Zhaoyi Li, Yan Hu, Yacong An, Jinhong Duan, Xundou Li, Xian-Da Yang   +5 more
doaj   +1 more source

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.

Blood Cancer Discovery, 2023
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and
G. Lancman, Kian Parsa, K. Kotlarz, Lisa Avery, Alaina Lurie, Alex Lieberman-Cribbin, H. Cho, Samir Parekh, S. Richard, J. Richter, C. Rodriguez, Adriana C Rossi, Larysa J Sanchez, S. Thibaud, Sundar Jagannath, A. Chari   +15 more
semanticscholar   +1 more source

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj  

Cancer immunomodulation using bispecific aptamers

Molecular Therapy: Nucleic Acids, 2022
Evasion of immune destruction is a major hallmark of cancer. Recent US Food and Drug Administration (FDA) approvals of various immunomodulating therapies underline the important role that reprogramming the immune system can play in combating this disease.
Brian J. Thomas, David Porciani, Donald H. Burke   +2 more
doaj   +1 more source

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure

Frontiers in Immunology, 2022
Immunotherapy with T cells genetically modified with chimeric antigen receptors (CARs) has shown significant clinical efficacy in patients with relapsed/refractory B-cell lymphoma.
Ana Carolina Caballero, Ana Carolina Caballero, Ana Carolina Caballero, Ana Carolina Caballero, Laura Escribà-Garcia, Laura Escribà-Garcia, Laura Escribà-Garcia, Carmen Alvarez-Fernández, Carmen Alvarez-Fernández, Carmen Alvarez-Fernández, Javier Briones, Javier Briones, Javier Briones, Javier Briones   +13 more
doaj   +1 more source

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

Blood Advances, 2023
Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell markers, including B-cell maturation antigen (BCMA), FcRH5, and G protein–coupled ...
Gemma K Reynolds, E. Cliff, G. R. Mohyuddin, R. Popat, S. Midha, Melissa Ng Liet Hing, S. Harrison, A. Kesselheim, B. Teh   +8 more
semanticscholar   +1 more source

Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers

Frontiers in Immunology, 2023
T cell engagers, a category of T cell-retargeting immunotherapy, are rapidly transforming clinical cancer care. However, the lack of tumor-specific targets poses a significant roadblock for broad adaptation of this therapeutic modality in many ...
Even Walseng, Bo Wang, Chunning Yang, Pooja Patel, Chihao Zhao, Hanzhi Zhang, Peng Zhao, Yariv Mazor   +7 more
doaj   +1 more source

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood, 2022
T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with hematologic malignancies; however, resistance and subsequent relapse remains a major challenge.
N. Zieger, M. Kazerani, Alyssa Nicholls, B. Vick, Jan Wulf, T. Straub, Michael Scheurer, Amelie Muth, G. Hänel, D. Nixdorf, M. Sponheimer, Malte Ohlmeyer, Sonja M Lacher, B. Brauchle, Anetta Marcinek, L. Rohrbacher, A. Leutbecher, K. Rejeski, O. Weigert, Michael von Bergwelt-Baildon, S. Theurich, R. Kischel, I. Jeremias, V. Bücklein, M. Subklewe   +24 more
semanticscholar   +1 more source

Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma

British Journal of Haematology, 2023
Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM).
Meera Mohan, R. Chakraborty, S. Bal, A. Nellore, Muhamed Baljevic, Anita D’Souza, P. Pappas, J. Berdeja, N. Callander, Luciano J Costa   +9 more
semanticscholar   +1 more source